Everything below concerns clinical evidence. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-25. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
The nitrogen of the ethanamine (and no other atoms of the side chain) is included in a cyclic structure. The phenyl ring of the benzyl system is substituted by an alkoxy group containing three carbon atoms. The 5- position of the benzimidazole system is substituted by a nitro group.
Guanylate cyclase (EC 4.6.1.2, also known as guanyl cyclase, guanylyl cyclase, or GC; systematic name GTP diphosphate-lyase (cyclizing; 3′,5′-cyclic-GMP-forming)) is a lyase enzyme that converts guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) and pyrophosphate:
=== Da === Valerie Daggett (BS 1993). American protein chemist at the University of Washington, known for molecular dynamics simulations of proteins and other biomolecules. John Call Dalton (1825–1889). American physiologist at the New York Metropolitan Board of Health, known for detailed and precise sketches of the brain. John W. Daly (1933–2008). American biochemist at the NIH, working primarily on alkaloids. Member Natl. Acad. Sci. USA. Marie Maynard Daly (1921–2003). American biochemist at the Albert Einstein College of Medicine, who studied the chemistry of histones, protein synthesis, the relationships between cholesterol and hypertension, and uptake of creatine by muscle cells. Keith Dalziel FRS (1921–1994). British biochemist at Oxford University, pioneer in analysis of the kinetics of two-substrate enzyme-catalysed reactions. Carl Peter Henrik Dam (1895–1976). Danish biochemist and physiologist at Copenhagen University who discovered vitamin K and its role in human physiology. Nobel Prize in Physiology or Medicine (1943). Marguerite Davis (1887–1967). American biochemist at the University of Wisconsin, co-discoverer of vitamins A and B Ronald W. Davis (b. 1941). American biochemist and geneticist at Stanford, known for developing new technologies in genomics. Member Natl. Acad. Sci. USA. Jean Dausset (1916–2009). French immunologist at INSERM who worked on the major histocompatibility complex. Nobel Prize in Physiology and Medicine (1980). Member Natl. Acad. Sci. USA. Member of the French Academy of Science Margaret Oakley Dayhoff (1925–1983).
Sydney Harbour A unit of volume used in Australia for water. One Sydney Harbour is the amount of water in Sydney Harbour: approximately 562 gigalitres (562,000,000 cubic metres, or 0.562 cubic kilometres); or in terms of the more unusual measures above, about 357 Melbourne Cricket Grounds, 238,000 Olympic Swimming pools, or 476,000 acre-feet. The Grand Canyon With a volume measure approximately 4 orders of magnitude greater than Sydney Harbour, the volume of the Grand Canyon may be used to visualize even larger things, like the magma chamber underneath Yellowstone and other things. According to the National Park Service, the volume of the Grand Canyon is 4.17 trillion cubic metres (5.45 trillion cubic yards) which is 4,170 km3 (1,000 mi3).
Sources: en.wikipedia.org
== History and etymology == The technique of smoke-drying jalapeños can be traced back to the early food preservation practices used in Mesoamerica, even before the Aztecs. The name comes from the Nahuatl word chīlpoctli (pronounced [t͡ʃiːlˈpoːkt͡ɬi]), meaning 'smoked chili'.
The prevalence of undernutrition is highest among children under five. In 2024, 150.2 million children under five years old were stunted, 42.8 million were wasted, and 35.5 million were overweight or obese. In 2021, an estimated 45% of deaths in children were linked to undernutrition. As of 2020, the prevalence of wasting among children under five in South Asia was reported to be 16% moderately or severely wasted. As of 2022, UNICEF reported this prevalence as having slightly improved, but still being at 14.8%. India has one of the highest burdens of wasting in Asia with over 20% wasted children. However, the burden of undernutrition among under-five children in African countries is much higher. A pooled analysis of the prevalence of chronic undernutrition among under-five children in East Africa was identified to be 33.3%. This prevalence of undernutrition among under-five children ranged from 21.9% in Kenya to 53% in Burundi. In Tanzania, the prevalence of stunting, among children under five varied from 41% in lowland and 64.5% in highland areas. Undernutrition by underweight and wasting was 11.5% and 2.5% in lowland and 22.% and 1.4% in the highland areas of Tanzania respectively. In South Sudan, the prevalence of undernutrition explained by stunting, underweight and wasting in under-five children were 23.8%, 4.8% and 2.3% respectively. In 28 countries, at least 30% of children were still affected by stunting in 2022. Vitamin A deficiency affects one third of children under age 5 around the world, leading to 670,000 deaths and 250,000–500,000 cases of blindness.
On 21 September, Pakistan launched airstrikes on the provinces of Paktika and Kunar in retaliation for the Kohat attack. Kunar's Nurgal district was hit at 4:00 local time, striking a family home and killing three family members and four others. Paktika's Barmal district was hit at 3:00, a shop and an unoccupied house were destroyed in the bombardment. Pakistani authorities denied striking civilians and said the attacks struck militant hideouts perfectly, supposedly killing 28 militants and multiple suicide bombers. On 22 September, it was reported that several Pakistani Taliban members attempted to cross the border at Kurram from Nangarhar and Paktia in Afghanistan. After being identified by Pakistani troops, they reportedly began firing on Pakistani checkposts. In retaliation, Pakistani troops launched multiple attacks on Afghan checkposts and defensive positions, supposedly causing several to flee. On 23 September, there were supposedly drone strikes inside Pakistan. While Pakistan blamed Afghanistan, Taliban officials denied the use of drones. On 24 September, Pakistan carried out airstrikes on 10 sites in Afghanistan. Kandahar, Paktia and Khost were struck and at least four civilians were killed. Afghanistan vowed to respond. The same day, local Afghan sources like Hariyat Media claimed that a Pakistani drone was intercepted over the Garmsir district near a Taliban border brigade position. On 27 September, Afghanistan's Defence Ministry claimed that 28 fighters were killed in Nuristan who had crossed the border from Pakistan.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.